Plain-English translation of NCT06909474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a treatment called CD5-targeted CAR-NK therapy, which uses specially designed immune cells to fight T-cell blood cancers. These engineered cells are designed to recognize and attack cancer cells that have a specific marker called CD5. The goal is to find the best dose of this treatment and learn how safe and effective it is for people whose cancer has come back or stopped responding to standard chemotherapy.
People with certain T-cell blood cancers often find that standard chemotherapy stops working or their cancer returns. This new treatment offers a different approach by using the body's own immune system to target and destroy cancer cells, which may help patients who have limited other options.
You likely qualify if…
You likely don't qualify if…
If you qualify for this trial, you would receive an infusion of the engineered immune cells on Day 0. Your doctors would then monitor you closely, checking your response to treatment around Day 28. If your cancer doesn't respond well enough and it remains safe to do so, you may receive a second infusion after Day 28. Throughout the trial, you'll have regular appointments for blood tests and scans to track how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Enrollment target
~15 participants
Started
March 2025
Primary completion
March 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jia Wei, MD
Chongqing Precision Biotech Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.